Latest News

Evaluating, implementing, and optimizing automation technologies that improve safety, efficiency, and patient care outcomes are practical strategies for health-system pharmacy leaders.

This FAQ outlines current measles cases, key drivers of increasing cases, and the essential role pharmacists play in vaccination, patient counseling, case recognition, and combating vaccine misinformation.

Supported by improved progression-free survival outcomes in the phase 3 ASCENT-03 and ASCENT-04/KEYNOTE-D19 trials, sacituzumab govitecan-hziy received FDA approval as both a monotherapy and combination therapy with pembrolizumab.

Pharmacists who understand the workflow before July 1 will be the ones patients and prescribers depend on when the program launches.

The FDA grants fast track designation to VS-7375, an oral KRAS G12D dual ON/OFF inhibitor, advancing new hope for pretreated non–small cell lung cancer (NSCLC).

The agent is to be used alongside diet adjustments in adult patients.

The FDA approved palbociclib-based maintenance therapy for HR-positive, HER2-positive advanced breast cancer following a significant progression-free survival benefit in PATINA.

As these tools continue to move into mainstream diabetes management, it is increasingly important that pharmacists have proficiency.

Marijuana’s move to Schedule III has reignited a long-standing contradiction.

The new indication is for those aged 12 years and older with unresectable or metastatic SS who received prior chemotherapy and are positive for certain genetic subtypes.

On GLP-1s like semaglutide or tirzepatide, weight loss can mean muscle loss; encourage patients to use protein and resistance training to stay strong.

Understanding this rapidly evolving therapeutic landscape will be essential as obesity pharmacotherapy continues to transform diabetes and cardiometabolic care.

Incorporate important health screenings and lifestyle prevention tips in MTM consults.

From AI-driven dispensing to grassroots advocacy wins, here are the key insights Pharmacy Times gathered at McKesson ideaShare 2026 in Denver.

Specialty dispensing and infusion services offer real opportunity—but the path requires careful planning, sequencing, and the right resources.

Single-cell findings presented at EHA 2026 identify B cells as potential drivers of immune dysregulation in acquired hemophilia A.

Ammoxetine is a novel SNRI derived from duloxetine, exhibiting a 3- to 10-fold greater potency.

Leonard Egede explains why PHQ-9 screening belongs in every cardio-kidney-metabolic (CKM) syndrome risk assessment—and how community pharmacists can reach patients the formal system misses.

The multiple myeloma (MM) approval was based on phase 3 IRAKLIA data demonstrating noninferior efficacy and reduced infusion-related reactions compared with intravenous administration.

Pharmacists cut through probiotic hype by matching strains and doses to evidence, checking shelf-life potency, and navigating confusing regulations.

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.